For the best experience we recommend upgrading to the latest version of these supported browsers:
I wish to continue viewing on my unsupported browser
For the best experience we recommend upgrading to the latest version of these supported browsers:
I wish to continue viewing on my unsupported browser
The Yuvedo Foundation commissioned a NERA team led by former Managing Director Prof. Dr. Frank Maier-Rigaud to explore the incentives to develop new drugs, in particular in the area of neurodegenerative diseases (NDD) such as Parkinson’s disease (PD).
Prof. Dr. Frank Maier-Rigaud and his team, Robert Lauer, Dr. Laura Robles, and Johannes Mattke, prepared a report for the Yuvedo Foundation that explores and compiles possible economic explanations that may be responsible for the lack of causal or disease-modifying treatments for some NDD such as PD. These economic explanations, which are alternative or possibly complementary to scientific challenges in the development of new drugs, are developed based on a review of the economic literature, including health economics, industrial economics, regulation, and finance theory. They are also based on qualitative interviews and existing empirical and qualitative studies in NDD and in particular PD. In addition, normative economics is used to determine if any incentives in place lead to socially optimal market outcomes or may give rise to market or regulatory failures.
The report found the following:
The Yuvedo Foundation published the NERA report on their webpage. You can find the report also on SSRN. For a short presentation by Prof. Dr. Maier-Rigaud, see here (at minutes 26:50-34:50).